Vebreltinib (Wanbirui) is a prescription drug and can only be purchased with a doctor’s prescription. The primary purchasing channels are the pharmacy of the treating hospital and specialized pharmacies operated by large pharmaceutical groups such as Sinopharm.
Purchasing Channels and Prerequisites
A valid prescription is mandatory for purchase
As an oncology therapeutic, Vebreltinib is a prescription drug that can only be dispensed upon a prescription issued by a specialist, based on the patient’s diagnosis and genetic testing results.
Main purchasing channels
Hospital pharmacy
Following confirmed diagnosis and prescription issuance, the most direct purchasing channel is the pharmacy of the hospital where the patient receives treatment.
Designated specialized pharmacies
Specialized pharmacies of major pharmaceutical distribution enterprises (e.g., Sinopharm) across regions may also stock the drug, which still requires a valid prescription for purchase.
Online pharmacies
In theory, qualified and legitimate pharmaceutical e-commerce platforms may supply this drug. However, when purchasing online, it is imperative to select reputable, fully licensed platforms and complete a rigorous prescription verification process. Given the specialized nature of the drug, extra vigilance is required regarding the reliability of online channels and drug traceability; priority is recommended for physical hospital or pharmacy channels.
Drug Information and Patient Support
Indications and guideline recommendations
Vebreltinib is primarily indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations, as well as specific subtypes of glioma with PTPRZ1-MET (ZM) fusion gene that have relapsed following standard therapy. The drug has been recommended by multiple authoritative domestic guidelines, including the Chinese Medical Association Clinical Practice Guidelines for Lung Cancer (2024 Edition).
Medical insurance coverage and price reference
Vebreltinib has been incorporated into the 2024 National Reimbursement Drug List, allowing patients to claim reimbursement per local policies, which substantially alleviates the financial burden. Actual prices fluctuate significantly based on region, purchasing channel, and medical insurance reimbursement ratios.
Patient assistance program
To support sustained treatment for patients, the Marketing Authorization Holder (Beijing Purino Biological Technology Co., Ltd.) operates a patient assistance program (e.g., the Wanbirui Patient Assistance Program). Eligible patients may receive complimentary subsequent doses after purchasing a specified quantity at their own expense. For detailed eligibility criteria and application procedures, consult the attending physician or the program’s official channels.
